The Drug Affordability Unit implements P.L. 2023, c. 106, pursuant to which manufacturers, carriers, pharmacy benefits managers, wholesalers, and pharmacy services administrative organizations register with and report information to the Division to enhance prescription drug price transparency. The Division will prepare an annual report “to make clear the major components of prescription drug pricing along the supply chain, and the impacts on insurance premiums and consumer cost sharing.” The Drug Affordability Council created by P.L. 2023, c. 106 will use these annual reports to formulate legislative and regulatory policy recommendations.
